Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 7 | 2024 | 586 | 1.860 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2024 | 66 | 1.560 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 132 | 1.000 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2024 | 883 | 0.640 |
Why?
|
| Histocompatibility Antigens | 1 | 2019 | 102 | 0.590 |
Why?
|
| Phthalazines | 1 | 2019 | 64 | 0.590 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 84 | 0.570 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2019 | 141 | 0.540 |
Why?
|
| Piperazines | 1 | 2019 | 381 | 0.500 |
Why?
|
| Genital Neoplasms, Female | 2 | 2020 | 99 | 0.300 |
Why?
|
| Intrauterine Devices | 1 | 2019 | 29 | 0.300 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 74 | 0.300 |
Why?
|
| Surgical Oncology | 1 | 2019 | 30 | 0.300 |
Why?
|
| Cancer Pain | 1 | 2019 | 36 | 0.290 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 2197 | 0.280 |
Why?
|
| Neoplasms | 1 | 2023 | 2884 | 0.260 |
Why?
|
| Pain Management | 1 | 2019 | 405 | 0.230 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 75 | 0.210 |
Why?
|
| Teratoma | 1 | 2016 | 120 | 0.210 |
Why?
|
| Polycomb-Group Proteins | 1 | 2023 | 36 | 0.200 |
Why?
|
| Struma Ovarii | 1 | 2022 | 8 | 0.190 |
Why?
|
| Lysine | 1 | 2023 | 302 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 642 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1143 | 0.160 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 13 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 154 | 0.160 |
Why?
|
| Enoxaparin | 1 | 2020 | 67 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 309 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 346 | 0.140 |
Why?
|
| Pyridones | 1 | 2020 | 199 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 931 | 0.140 |
Why?
|
| Female | 11 | 2024 | 78376 | 0.130 |
Why?
|
| Sarcoma | 1 | 2020 | 205 | 0.130 |
Why?
|
| Peptides | 1 | 2023 | 998 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 442 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 930 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 750 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2020 | 510 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 324 | 0.120 |
Why?
|
| Humans | 12 | 2024 | 144957 | 0.110 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2020 | 64 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2020 | 724 | 0.110 |
Why?
|
| Histones | 1 | 2019 | 670 | 0.100 |
Why?
|
| Animals | 3 | 2024 | 38109 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1786 | 0.090 |
Why?
|
| Disease Progression | 1 | 2019 | 2852 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3550 | 0.090 |
Why?
|
| Gynecology | 1 | 2020 | 178 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2920 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 285 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2019 | 380 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 70 | 0.060 |
Why?
|
| Middle Aged | 5 | 2021 | 35928 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2016 | 256 | 0.050 |
Why?
|
| Cisplatin | 1 | 2016 | 334 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 339 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 8279 | 0.050 |
Why?
|
| Incidence | 1 | 2019 | 2883 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 137 | 0.050 |
Why?
|
| Mice | 1 | 2019 | 18365 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2019 | 17101 | 0.040 |
Why?
|
| Vulvectomy | 1 | 2020 | 2 | 0.040 |
Why?
|
| Dermatofibrosarcoma | 1 | 2020 | 7 | 0.040 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2020 | 5 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 28 | 0.040 |
Why?
|
| Liposarcoma | 1 | 2020 | 31 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 64 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 224 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 206 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 173 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 334 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 5965 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 14126 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 847 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1385 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 966 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1325 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2092 | 0.030 |
Why?
|
| Aged | 2 | 2020 | 25947 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2456 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 40506 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 11695 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 3192 | 0.020 |
Why?
|
| United States | 1 | 2020 | 15988 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 22453 | 0.010 |
Why?
|